Virtual Library

Start Your Search

E. Dalakou

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      229P - Clinical and laboratory markers of prognosis in lung cancer patients with hypercalcemia (ID 329)

      12:30 - 13:00  |  Author(s): E. Dalakou

      • Abstract
      • Slides

      Hypercalcemia is a severe complication in lung cancer patients, imposing prompt recognition, investigation and treatment. The primary aim of our study was to further investigate the clinical and laboratory prognostic features in a cohort of lung cancer patients with hypercalcemia.

      The medical records of a total of 100 sequential, non-selected, patients with histologically or cytologically-confirmed diagnosis of small or non-small cell lung cancer (SCLC/NSCLC) and hypercalcemia, diagnosed and treated at the Oncology Unit of Sotiria Athens General Hospital between December 2015 to April 2016 were retrospectively reviewed. Demographic, clinical and laboratory patients’ characteristics were correlated with outcome data.

      Mean age (±SD) of our patient population at the diagnosis of hypercalcemia was 64.3 (±8,8) years; male to female ratio was 86/14. The albumin-corrected calcium was 11.0 ± 0.6 mg/dl (range 10.5–13.9). The majority of patients had non-small cell lung cancer (89%), mainly of squamous type (48.3%) and adenocarcinoma (43.8%), and stage IV disease (57%). Development of bone metastases (BMs) was observed in 17.7% of patients, while 5% of patients had received bisphosphonates. Hypercalcemia-leukocytosis syndrome was associated with advanced stage (p = 0.001) and the presence of bone metastases (p < 0.05). Median time to progression was 3.5 months (interquartile range: 1.2–7.2) and median overall survival (mOS) was 13.8 months (95% CI: 7.3–20.2). In univariate Cox proportional hazard models, patients with lower serum albumin levels (p < 0.001), concomitant presence of leukocytosis (p < 0.05), advanced disease stage (p < 0.01) and negative history of resected disease (p < 0.001) had higher risk of death. In multivariate Cox regression analysis, serum albumin (HR 0.37, 95% CI 0.16–0.86; p < 0.05), metastatic disease (HR 1.92, 95% CI 1.01–3.68; p < 0.05) and the history of surgical resection (HR 0.25, 95%CI 0.10–0.61; p < 0.01) were independent predictors of survival.

      Our study results, derived from a combined cohort of SCLC and NSCLC patients with hypercalcemia, suggest that serum albumin levels may provide independent prognostic information in this setting.

      Clinical trial identification:

      Legal entity responsible for the study:
      University of Athens

      Has not received any funding

      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.